Featured, Medical Marijuana

Canadian LP’s and biotech present hot opportunities for investors

Canadian LP's and biotech present hot opportunities for investors

2017 has been a major year for the legal marijuana industry and the year has been highlighted by new countries and continents legalizing medical marijuana, a burgeoning Canadian market, and a confusing landscape in the United States.

We continue to view the legal marijuana industry as one of the top places to invest. The industry is the fastest growing industry in the world and it offers investors access to investment opportunities that are levered to this growth.

While many people typically think about a dispensary when they think about a marijuana investment, there is many more opportunities available that are less capital intensive and just as exciting.

Today, we want to highlight our two favorite sub-sectors of the legal marijuana industry and provide insight into some of the top opportunities in each sub-sector.

Biotech Cannabis Stocks: A Hot Opportunity

The biotech sector will be one of the greatest beneficiaries of the legal marijuana boom.

Biotech companies focused on medical marijuana possess the greatest upside potential as they work to develop treatments derived from marijuana, which can be used to improve daily life for millions of people throughout the world.

GW Pharmaceuticals (GWPH) is our top pick in the biotech cannabis sector and the company owns one of the largest and most advanced pipeline of product candidates. GW is changing the landscape of the biotech industry and already sells a cannabis-derived treatment for multiple sclerosis is 27 countries.

GW Pharma is a company that investors need to watch as it continues to execute on its pipeline and create value for shareholders. We are favorable on GW’s long-term opportunity and view GW as one of the best cannabis investment opportunities.

Our bullish view is due to GW’s extensive pipeline of products in advanced stages of FDA testing, its balance sheet which is strong enough to support the cost of clinical trials, its impressive Wall Street coverage, and the $390 acquisition price placed on the company by Goldman Sachs (GS).

Canada Continues to Lead

Canadian licensed medical marijuana producers continue to gain attention as the sector executes and increases its global market share of the legal marijuana industry.

credit:420intel.com

Related Posts